Povetacicept Shows Promising Interim Results in Phase 3 Trial for IgA Nephropathy
Interim analysis of a phase 3 trial demonstrates povetacicept's efficacy in reducing proteinuria and pathological markers in IgA nephropathy, with a favorable safety profile.